Skip Navigation

Cardiovascular Research 2006 70(2):391-398; doi:10.1016/j.cardiores.2005.07.005
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Monnet, X.
Right arrow Articles by Berdeaux, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monnet, X.
Right arrow Articles by Berdeaux, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Phenotypic adaptation of the late preconditioned heart: Myocardial oxygen consumption is reduced

Xavier Monneta,b,c, Bijan Ghaleha,b,c,d, Laurence Lucatsa,b,c, Patrice Colina,b,c, Roland Zinia,b,c, Luc Hittingera,b,c,d and Alain Berdeauxa,b,c,d,*

aINSERM U660, Créteil, F-94010, France
bEcole Nationale Vétérinaire d'Alfort, Maisons-Alfort, F-94700, France
cLaboratoire de Pharmacologie, Faculté de Médecine de Créteil, Université Paris XII, Créteil, F-94000, France
dFédération de Cardiologie, Hôpital Henri Mondor, Créteil, France

* Corresponding author. Laboratoire de Pharmacologie, INSERM U660, Faculté de Médecine de Créteil, 8, rue du Général Sarrail, 94010 Creteil Cedex, France. Tel.: +33 1 49 81 36 51; fax: +33 1 49 98 17 77. Email address: berdeaux{at}im3.inserm.fr

Received 18 April 2005; revised 6 July 2005; accepted 11 July 2005


   Abstract
Top
 Abstract
1. Introduction
 2. Methods
 3. Results
 4. Discussion
 Acknowledgments
 References
 
Objectives Although the signalling pathways of late preconditioning have been extensively investigated, its consequence for myocardial metabolism remains unknown. Thus, myocardial oxygen consumption (MVO2) was evaluated before and under late preconditioning.

Methods In 7 chronically instrumented dogs, we measured MVO2 in vivo at baseline and during inotropic stimulation with dobutamine (10 and 20 µg/kg/min, i.v.) before (Day 0) and 24 h after (Day 1) a 10-min circumflex coronary artery occlusion.

Results At Day 0, dobutamine dose-dependently increased the triple product (heart rate x left ventricular systolic pressure x left ventricular maximum dP/dt), MVO2, coronary blood flow, and coronary sinus pO2. At Day 1, the triple product was similar at baseline and at each dose of dobutamine but MVO2 was significantly blunted as compared to Day 0 (– 15±4%, – 22±3% and – 19±4% at baseline, dobutamine 10 and 20 µg/kg/min, respectively). Importantly, the relationship between MVO2 and triple product was significantly rightward shifted with late preconditioning, i.e., MVO2 was reduced for any level of triple product. At Day 1, the relationship between coronary blood flow and MVO2 was not altered as compared to Day 0 but coronary sinus pO2 was significantly increased vs. Day 0 for any level of coronary blood flow, suggesting that late preconditioning exerted no vasomotor effect but rather changed myocardial oxygen handling. These effects were abolished by administration of S-methyl-isothiourea (1.5 mg/kg, i.v.), a iNOS inhibitor.

Conclusion This study demonstrates that ischemic late preconditioning is characterized by a major reduction in MVO2, both at baseline and under inotropic stimulation. NO from iNOS contributes to this modification of metabolic phenotype.

KEYWORDS Oxygen consumption; Stunning; Nitric oxide; Preconditioning


   1. Introduction
Top
 Abstract
 1. Introduction
2. Methods
 3. Results
 4. Discussion
 Acknowledgments
 References
 
Late preconditioning is a cardioprotective phenomenon which develops 24 h after a brief ischemic episode leading to a reduction in infarct size [23] as well as in the severity and duration of myocardial stunning [32,34]. Numerous mechanisms have been proposed to explain the protective effect of late preconditioning [42]. Indeed, increased heat shock proteins such as hsp 27 [9], hsp 70 [21], hsp 72 [20] as well as enhanced MnSOD activity [13,41] have been proposed as possible mechanisms for this protection. It is also now well demonstrated that nitric oxide (NO) plays a major role as a trigger and mediator of late preconditioning [4]. Different isoforms of NO synthase (NOS) might be involved in this phenomenon [14,16,40,41] and iNOS was demonstrated to be upregulated during the second window of preconditioning in both rabbits [14,41] and dogs [15]. Although the signaling pathways leading to late preconditioning have been extensively investigated during the past years, little is known about the functional implications of this increase in NO production. In this setting, Kim et al. [15] have reported an enhanced iNOS activity in the contraction of myocytes isolated from late preconditioned dog hearts. However, the consequences of NOS upregulation on myocardial metabolism of the late preconditioned heart have never been yet investigated. Indeed, evidence for a role of NO on mitochondrial function has been reported since 1982 [11] and NO has been demonstrated to reduce oxygen consumption in various physiological as well as pathological conditions in the heart [1,2,5,27,28,31,37] as well as in other organs [17,30,31]. Indeed during classical ischemic preconditioning, a reduction in myocardial metabolism assessed by a preservation of ATP [22] as well as a decrease in both energy demand [18] and myocardial oxygen consumption [35] have already been demonstrated. Whether myocardial oxygen consumption is altered during the late phase of preconditioning and whether such alteration is a feature of this cardioprotection has never been studied yet.

Therefore, the first goal of our study was to determine whether myocardial oxygen consumption (MVO2) is modified 24 h after a brief coronary artery occlusion (CAO). For this purpose, we used a model of chronically instrumented conscious dogs that enables in vivo to repeat CAO 24 h apart and to extensively monitor hemodynamic and metabolic parameters [7,10]. MVO2 was measured at baseline and during inotropic stimulation with graded doses of dobutamine. The potential modulatory role of NO/iNOS on MVO2 was investigated by administrating S-methyl-isothiourea (SMT), an iNOS inhibitor [3,24].


   2. Methods
Top
 Abstract
 1. Introduction
 2. Methods
3. Results
 4. Discussion
 Acknowledgments
 References
 
The investigation conforms with the Guide for the Care and Use of Laboratory Animals (NIH publication no. 85-23, revised 1996).

2.1 Instrumentation
Seven dogs (17–24 kg) were anesthetized with pentobarbitone sodium (30 mg/kg i.v.), intubated and mechanically ventilated with a Harvard respirator (South Natick, MA, USA). The anesthesia was maintained with additional administrations of pentobarbitone sodium. Under sterile surgical conditions, a left thoracotomy (5th intercostal space) was performed. The heart was suspended in a pericardial cradle. Fluid-filled Tygon catheters were placed in the descending thoracic aorta and the left atrium for measurements of blood pressures. Silastic catheters were implanted in the pulmonary artery for drug administration and in the coronary sinus with the tip leading away from the right atrium for venous blood sampling. A solid-state pressure transducer (P7A, Konigsberg Instruments; Pasadena, CA, USA) was introduced into the apex of the left ventricle (LV). A coronary flow probe (Transonic Systems; Ithaca, NY, USA) and a pneumatic occluder were placed on the left circumflex coronary artery. Two pairs of ultrasonic crystals were used for measurement of left ventricular (LV) wall thickening in the distribution of the left circumflex (posterior zone) and the left anterior descending (anterior zone) coronary arteries. One crystal was implanted in the endocardium and the other was sutured to the epicardium. Finally, bipolar electrodes were sewn on the left atrial appendage for subsequent pacing. All catheters and wires were exteriorized between the scapulae, and the pneumothorax was evacuated through a chest tube inserted in the sixth intercostals space. Cefazolin (1 g i.v.) and gentamicin (40 mg i.v.) were administered before and during the first week after surgery. Post-operative analgesia was provided with morphine and buprenophine.

2.2 Hemodynamic measurements
All hemodynamic data were recorded and analyzed using the data acquisition software HEM v3.3 (Notocord Systems; Croissy sur Seine, France). Aortic and left atrial pressures were measured with a Statham P23 ID strain-gauge transducer (Gould-Nicolet; Courtaboeuf, France). Mean coronary blood flow (CBF) was measured using a transit-time flowmeter (Transonic T206, Transonic Systems; Ithaca, NY, USA). LV pressure was measured using the Konigsberg gauge and the change in LV pressure over time (LV dP/dt) was computed from the LV pressure signal. LV pressure was calibrated in vitro with a mercury manometer and in vivo with the left atrial and aortic pressures. Cardiac work was estimated by the triple product as heart rate x systolic arterial pressure x LV dP/dtmax.

2.3 Measurements of LV wall thickness
Wall thicknesses were obtained by using an ultrasonic transit-time dimension gauge (Module 201, System 6, Triton Technology Inc.; San Diego, CA, USA). To determine wall thickening, end-diastolic wall thickness was measured at the initiation of the upstroke of LV pressure tracing and the end-systolic wall thickness was measured 20 ms before peak negative LV dP/dt. Percent wall thickening was defined as end-systolic thickness minus end-diastolic thickness times 100 divided by end-diastolic thickness.

2.4 LV oxygen consumption
Measurement of oxymetric parameters was made with a blood gas apparatus and a co-oxymeter. Oxygen consumption was calculated as the product of CBF and the arteriovenous difference in the oxygen content. The arteriovenous difference in oxygen content was measured between the arterial oxygen content and the coronary sinus oxygen content.

2.5 Myocardial nitrate–nitrite measurements
Blood samples obtained from the aortic and the coronary sinus catheters for determination of NOx (total plasma nitrite and nitrate concentrations) were collected into heparinized syringes. After centrifugation, plasma NOx was determined using a fluorometric assay (Cayman fluorimetric nitrate–nitrite assay kit, Ann Arbor, MI, USA). The coronary arteriovenous difference of NOx was obtained by subtracting coronary venous from aortic NOx. The coronary production of NOx (MNOx, nmol/l) was calculated by multiplying the arteriovenous difference by the corresponding mean coronary blood flow.

2.6 Experimental protocol
The experiments were conducted 3–4 weeks after surgery when the dogs were healthy and apyretic. At Day 0, when dogs were lying quietly on a table, a first set of hemodynamic measurements was performed and a first blood sample was collected for blood gas analysis. Dobutamine was then infused i.v. continuously during 5 min at 10 µg/kg/min. Hemodynamic and oxymetric parameters were measured once hemodynamic stability was achieved. The rate of dobutamine infusion was then increased at 20 µg/kg/min during 5 min and a third set of measurements was recorded at stability. Another day, a 10-min circumflex coronary artery occlusion (CAO) was performed by complete inflation of the pneumatic occluder.

Twenty-four hours after CAO (Day 1), hemodynamic and oxymetric parameters were measured at baseline and during dobutamine infusion (10 and 20 µg/kg/min during 5 min). When hemodynamics had returned to baseline values, SMT (S-methyl-isothiourea) was administered (1.5 mg/kg, iv). Thirty minutes later, infusion of dobutamine (10 and 20 µg/kg/min during 5 min) associated with hemodynamic and oxymetric measurements was repeated again. In order to strictly control heart rate for MVO2 measurements and to avoid the confounding effect of potential slight variations in heart rate [7], all measurements at Day 0 and Day 1 before SMT as well as at Day 1 after SMT were performed under atrial pacing (spontaneous heart rate at baseline and under dobutamine observed at Day 0+10 beats/min), i.e., comparisons of MVO2 values within each animal were performed at the same heart rate.

The selected dose of SMT was based on preliminary experiments performed in additional 4 dogs showing that it was the highest one that did not induce any significant hemodynamic changes. Furthermore, we tested that the CBF responses to acetylcholine (0.3 to 3 µg/kg, i.v.) were similar in the absence and presence of SMT. In addition, MVO2 measured at baseline and during dobutamine infusion (10 and 20 µg/kg/min during 5 min) were not altered by SMT. This is illustrated in Fig. 1 showing the absence of changes in the relationship between MVO2 and the triple product by SMT in the non preconditioned state.


Figure 1
View larger version (13K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Relationship between myocardial oxygen consumption (MVO2, ml O2/min) and the triple product (heart rate x aortic systolic pressure x dP/dtmax, beats/mm Hg2/s2 x 105) measured at baseline and under dobutamine (10 and 20 µg/kg/min) before coronary artery occlusion, i.e., in the non-preconditioned state (n=4). Analysis of covariance revealed that this relationship was not altered by administration of SMT (SMT: S-methyl-isothiourea).

 
To ensure that late preconditioning against myocardial stunning was effective in each investigated animal, 10 days later, 2 episodes of 10-min CAO were performed 24 h apart and hemodynamic was recorded at spontaneous heart rate before CAO, during CAO and during the ensuing reperfusion period (6h).

2.7 Statistical analysis
Data are reported as mean±S.E.M. Comparisons were performed using two-way ANOVA for repeated measures. If needed, individual comparisons were then conducted using a paired Student's t-test with Bonferroni correction. In addition, linear regressions were performed and analysis of covariances were used to adjust a response variable for linear dependence on an investigated parameter after testing for parallel regression lines. A value of p<0.05 was considered significant.


   3. Results
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
4. Discussion
 Acknowledgments
 References
 
3.1 Hemodynamics
Hemodynamic data are summarized in Table 1. At Day 0, dobutamine dose-dependently increased the triple product to 21.3±2.3 and 33.3±3.6 105 beats/mm Hg2/s2 from 10.8±1.3 105 beats/mm Hg2/s2 at 10 and 20 µg/kg/min, respectively. Wall thickening in the posterior zone was also increased to 51±8% and 54±8% from 35±7% with dobutamine at 10 and 20 µg/kg/min, respectively. At Day 1, none of the hemodynamic parameters were significantly different vs. Day 0. In the anterior zone at Day 0, wall thickening increased to 44±6% and 46±7% from 30±5% during dobutamine infusion at 10 and 20 µg/kg/min, respectively. Similar increases were observed at Day 1 (42±8% and 45±7% from 29±6% during dobutamine infusion at 10 and 20 µg/kg/min, respectively). In addition, administration of SMT at Day 1 did not significantly alter mean arterial pressure, heart rate, triple product and wall thickening measured at baseline and during dobutamine infusion as compared to corresponding values measured at Day 0 and Day 1 without SMT.


View this table:
[in this window]
[in a new window]

  		Table 1 Hemodynamics

 
3.2 LV oxygen consumption
Fig. 2 and Table 2 show the CBF and oxymetric parameters. At Day 0, dobutamine infusion dose-dependently increased MVO2 to 7.6±0.8 and 9.5±1.1 ml O2/min from 4.7±0.3 ml O2/min at 10 and 20 µg/kg/min, respectively. CBF also increased from 35±2 ml/min at baseline to 58±6 ml/min and 76±9 ml/min at 10 and 20 µg/kg/min of dobutamine, respectively. Values of pcsO2 were simultaneously increased under dobutamine.


Figure 2
View larger version (23K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 Myocardial oxygen consumption (MVO2, ml O2/min) measured at baseline and under dobutamine (10 and 20 µg/kg/min) at Day 0, Day 1 without SMT and Day 1 plus SMT (SMT: S-methyl-isothiourea). MVO2 was reduced at Day 1 vs. Day 0 but this effect was abolished by administration of SMT. *p<0.05 vs. corresponding value at Day 0.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Coronary blood flow and oximetric parameters

 
At Day 1, baseline MVO2 was significantly reduced vs. Day 0 (4.1±0.5 vs. 4.7±0.3 ml O2/min, respectively). In addition, production of NOx was increased at Day 1 as compared to Day 0 (23±4 vs. 12±3 nmol/min, respectively, p<0.05). During dobutamine infusion, MVO2 increased to 6.0±0.7 and 7.7±0.8 ml O2/min from baseline at 10 and 20 µg/kg/min, respectively. These effects of dobutamine on MVO2 observed at Day 1 were however of lower magnitude as compared to corresponding ones at Day 0 (– 22±3% and – 19±4% at 10 and 20 µg/kg/min, respectively) (Fig. 2). Simultaneously, the dobutamine-induced increases in CBF were significantly reduced under dobutamine at Day 1 vs. Day 0 (– 13±4% and – 14±3% at 10 and 20 µg/kg/min, respectively) (Table 2). These effects of late preconditioning on CBF and oxymetric parameters were abolished after SMT administration (Table 2; Fig. 2). Values of hemoglobin and paO2 were not significantly different between Day 0, Day 1 without SMT and Day 1 plus SMT.

When MVO2 was plotted against the triple product (Fig. 3), analysis of covariance revealed that MVO2 was significantly reduced at Day 1 as compared to Day 0 for any level of the triple product. Administration of SMT abolished this effect as no statistical difference vs. Day 0 was observed.


Figure 3
View larger version (17K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 3 Relationship between myocardial oxygen consumption (MVO2, ml O2/min) and the triple product (heart rate x aortic systolic pressure x dP/dtmax, beats/mm Hg2/s2 x 105) measured at baseline and under dobutamine (10 and 20 µg/kg/min) at Day 0, Day 1 without SMT and Day 1 plus SMT (SMT: S-methyl-isothiourea). Analysis of covariance revealed that MVO2 was significantly reduced at Day 1 as compared to Day 0 for any level of triple product. Administration of SMT abolished this effect. *p<0.05 vs. Day 0.

 
Finally, analysis of covariance demonstrated that pcsO2 values measured at Day 1 were significantly higher than those measured at Day 0 for any level of CBF. This effect was abolished by the administration of SMT as illustrated in Fig. 4.


Figure 4
View larger version (13K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 4 Relationship between pcsO2 (mm Hg) and mean coronary blood flow (CBF, ml/min) measured at baseline and under dobutamine (10 and 20 µg/kg/min) at Day 0, Day 1 without SMT and Day 1 plus SMT (SMT: S-methyl-isothiourea). Analysis of covariance revealed that pcsO2 was significantly enhanced at Day 1 as compared to Day 0 for any level of CBF. Administration of SMT abolished this effect. *p<0.05 vs. Day 0.

 
3.3 Late preconditioning against myocardial stunning
At Day 0, CAO induced a dramatic decrease of LV wall thickening in the posterior zone (to – 1±2% from 40±8%) that progressively returned to its baseline value within 24 h. At Day 1, i.e., 24 h later, CAO induced a similar decrease in LV wall thickening but the recovery of this parameter was significantly greater during reperfusion vs. Day 0, demonstrating late preconditioning against myocardial stunning (Fig. 5).


Figure 5
View larger version (17K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 5 Evolution of posterior wall thickening measured at baseline (B), during coronary artery occlusion (CAO) and reperfusion at Day 0 and Day 1. The severity of myocardial stunning was reduced at Day 1 as compared to Day 0, indicating late preconditioning. *p<0.05 vs. Day 0.

 

   4. Discussion
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
Acknowledgments
 References
 
This study conducted in chronically instrumented conscious dogs demonstrates that (a) in the late preconditioned state, i.e., 24 h after a brief coronary occlusion, MVO2 is reduced at baseline as well as during an inotropic stimulation for a similar myocardial demand, (b) this reduction in MVO2 is related to a change in oxygen utilization and (c) NO related to iNOS contributes to this adaptation of the cardiac metabolic phenotype during late preconditioning as it is reversed by the administration of SMT. These results provide the first evidence that ischemic late preconditioning induces profound alterations in myocardial oxygen handling in a highly integrated experimental model.

The main result of this study is that in the preconditioned state, MVO2 measured at baseline and during increased oxygen demand secondary to inotropic stimulation was reduced for any level of cardiac work. Indeed, a significant rightward shift of the MVO2–triple product relationship was observed, demonstrating that a lower amount of O2 was necessary to provide the same level of contractile performance, thus suggesting an improvement in cardiac efficiency. Cardiac work and efficiency were not directly measured in this study but calculation of the triple product is known to be a reliable surrogate for cardiac work [26]. It is unlikely that changes in stroke volume, an important correlate of MVO2 [26], might explain these results as no significant hemodynamic changes were observed between Day 0 and Day 1.

In situations of increased cardiac work such as physical exertion [2,7], pcsO2 is know to decrease while MVO2 increases. There is a concomitant vasodilation and greater oxygen extraction allowing the heart to satisfy the increased oxygen demand. In our experimental conditions, dobutamine-induced increase in MVO2 was accompanied by both increases in CBF and pcsO2, related to the vasodilatory properties of dobutamine. Therefore, it should be stressed that vasodilation induced by dobutamine was beyond the sole metabolic autoregulation, allowing pcsO2 to increase while MVO2 is also increasing. Comparisons of Days 0 and 1 revealed that CBF under dobutamine was reduced and pcsO2 was increased during late preconditioning, concomitantly with the decrease in MVO2. Regarding these changes in pcsO2, we determined in preliminary experiments that the variability of pcsO2 measurements is as high as 4.8% in our conditions. The lack of any significant changes in the relationship between CBF and MVO2 suggests that the changes in MVO2 observed between Days 0 and 1 are unlikely to be the consequence of vasomotor alterations induced by late preconditioning. In addition, the relationship between pcsO2 and CBF was significantly leftward shifted, i.e., at any level of CBF, pcsO2 was increased at Day 1 vs. Day 0. Therefore, the reduction in MVO2 observed at Day 1 was more likely related to an improved myocyte oxygen utilization rather than an enhanced oxygen delivery to the myocardium.

In this study, we further investigated whether NO was involved in the metabolic adaptation observed at Day 1 as NO is known to play a key role during late preconditioning [3] and that NO exerts an inhibitory effect on MVO2 in normal hearts [1,2,27,28,31] although other studies found no effect [8,39] or an inverse effect [33]. This metabolic effect of NO has also been demonstrated in vivo during heart failure [36,37] and was related to NO produced by the inducible isoform of NO synthase [5]. Indeed, it is known that NO acts on oxygen consumption by nitrosylating the iron–sulfur centers of cytochrom C oxidase of the mitochondrial electron transport chain, of aconitase and of mitochondrial complexes I and II by competition with oxygen [6,11,12,38,39]. NO also regulates the glucose uptake of myocytes [40] and NOS inhibition leads to the switch of cardiac metabolic substrate from free fatty acids to lactate and glucose [2] with enhanced myocardial metabolic efficiency [25]. In this study, administration of SMT at Day 1 abolished the reduction in MVO2 induced by late preconditioning for similar levels of cardiac demand, suggesting that NO from iNOS was involved. Although we cannot exclude, it is unlikely that eNOS was affected by SMT in our experimental conditions as in preliminary experiments (see Methods), administration of SMT did not alter heart rate, mean arterial pressure, MVO2 and coronary blood flow responses to acetylcholine. Furthermore during late preconditioning, SMT did not significantly change the pcsO2–CBF as well as the CBF–MVO2 relationships as compared to Day 0. In preliminary experiments, we could observe in 2 dogs that administration of SMT was able to abolish late preconditioning against myocardial stunning (data not shown). Finally at Day 1, although the hemoglobin level was slightly but not significantly reduced after the SMT infusion at baseline, it is unlikely that this difference could explain the changes in MVO2 observed with SMT. Indeed, this difference in hemoglobin was only observed at baseline but not under dobutamine infusion, although the increases in MVO2 with SMT were observed both at baseline and under dobutamine. Furthermore, this difference in hemoglobin at baseline did not induce significant change in corresponding CBF.

Previous studies demonstrated that eNOS plays a major role in the physiological regulation of mitochondrial respiration or cardiac metabolism under physiological conditions [2,16,33,38]. Conversely, Chen et al. [5] demonstrated in an in vivo dog model of heart failure that the modulation of MVO2 by NO was related, at least in part, to iNOS activity. In an in vitro study, Loke et al. [19] demonstrated using hearts from eNOS– / – and iNOS– / – deficient mice that eNOS was responsible for MVO2 modulation in normal heart but iNOS was also implicated if mice were previously treated with endotoxin. Thus, it is interesting to speculate that the endothelial isoform of NO might be responsible for the NO-mediated MVO2 modulation in the normal setting [19,29] but that the inducible isoform of NOS would be rather implicated under pathological or adaptative conditions such as endotoxinic shock [19], heart failure [5] or late preconditioning. Accordingly, iNOS was demonstrated to be upregulated during the second window of preconditioning in rabbits [14,41] and in a dog model similar to that used in the present study [15]. We suggest that ischemic late preconditioning might represent another situation where NO acts as a potent regulator of MVO2 although we did not specifically investigated these mechanisms at the cellular level in our in vivo model. Because other NO synthase inhibitors induce major alterations in cardiac preload and afterload that might be confounding variables for analysing MVO2, it was not possible to investigate the role of eNOS in our experimental in vivo model and this is a limitation of our study.

In conclusion, this in vivo study demonstrates for the first time that ischemic late preconditioning is characterized by a major reduction in myocardial oxygen consumption both at baseline and under inotropic stimulation. This effect is more likely related to changes in oxygen handling rather than an effect on myocardial oxygen delivery. As this effect is blunted by SMT, it suggests that NO produced from iNOS contributes to this metabolic change.


   Acknowledgments
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
 Acknowledgments
References
 
This study was supported by grants from the Fondation de France (2001-005170 and 2003-005607), Bonus Qualité Recherche 2003 (University Paris XI, France) and ACI 2002 (Biologie du développement and physiologie integrative, 02-2-0511). The authors are greatly indebted to Alain Bizé, Stéphane Bloquet and Georges Zadigue for their excellent technical assistance.


   Notes
 
Time for primary review 20 days


   References
Top
 Abstract
 1. Introduction
 2. Methods
 3. Results
 4. Discussion
 Acknowledgments
 References
 

  1. Altman J.D., Kinn J., Duncker D.J., Bache R.J. Effect of inhibition of nitric oxide formation on coronary blood flow during exercise in the dog. Cardiovasc Res (1994) 28:119–124.[Abstract/Free Full Text]
  2. Bernstein R.D., Ochoa F.Y., Xu X., Forfia P., Shen W., Thompson C.I., et al. Function and production of nitric oxide in the coronary circulation of the conscious dog during exercise. Circ Res (1996) 79:840–848.[Abstract/Free Full Text]
  3. Bolli R., Manchikalapudi S., Tang X.L., Takano H., Qiu Y., Guo Y., et al. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res (1997) 81:1094–1107.[Abstract/Free Full Text]
  4. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol (2001) 33:1897–1918.[CrossRef][Web of Science][Medline]
  5. Chen Y., Traverse J.H., Du R., Hou M., Bache R.J. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation (2002) 106:273–279.[Abstract/Free Full Text]
  6. Cleeter M.W., Cooper J.M., Darley-Usmar V.M., Moncada S., Schapira A.H. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 345:50–54.[CrossRef][Web of Science][Medline]
  7. Colin P., Ghaleh B., Monnet X., Su J., Hittinger L., Giudicelli J.F., et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol (2003) 284:H676–H682.[Web of Science]
  8. Crystal G.J., Zhou X. Nitric oxide does not modulate the increases in blood flow, O2 consumption, or contractility during CaCl2 administration in canine hearts. Cardiovasc Res (1999) 42:232–239.[Abstract/Free Full Text]
  9. Dana A., Skarli M., Papakrivopoulou J., Yellon D.M. Adenosine A(1) receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism. Circ Res (2000) 86:989–997.[Abstract/Free Full Text]
  10. De Curzon O.P., Ghaleh B., Tissier R., Giudicelli J.F., Hittinger L., Berdeaux A. Myocardial stunning in exercise-induced ischemia in dogs: lack of late preconditioning. Am J Physiol (2001) 280:H302–H310.[Web of Science]
  11. Granger D.L., Lehninger A.L. Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells. J Cell Biol (1982) 95:527–535.[Abstract/Free Full Text]
  12. Hibbs J.B. Jr., Taintor R.R., Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science (1987) 23(235):473–476.[CrossRef]
  13. Hoshida S., Kuzuya T., Fuji H., Yamashita N., Oe H., Hori M., et al. Sublethal ischemia alters myocardial antioxidant activity in canine heart. Am J Physiol (1993) 264:H33–H39.[Web of Science][Medline]
  14. Jones W.K., Flaherty M.P., Tang X.L., Takano H., Qiu Y., Banerjee S., et al. Ischemic preconditioning increases iNOS transcript levels in conscious rabbits via nitric oxide-dependent mechanism. J Mol Cell Cardiol (1999) 34:1469–1481.
  15. Kim S.J., Kim Y.K., Takagi G., Huang C.H., Geng Y.J., Vatner S.F. Enhanced iNOS function in myocytes one day after brief ischemic episode. Am J Physiol (2002) 282:H423–H428.[Web of Science]
  16. Laude K., Favre J., Thuillez C., Richard V. NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection. Am J Physiol (2003) 284:H2053–H2060.[Web of Science]
  17. Laycock S.K., Vogel T., Forfia P.R., Tuzman J., Xu X., Ochoa M., et al. Role of nitric oxide in the control of renal oxygen consumption and the regulation of chemical work in the kidney. Circ Res (1998) 82:1263–1271.[Abstract/Free Full Text]
  18. Jennings R.B., Sebbag L., Schwartz L.M., Crago M.S., Reimer K.A. Metabolism of preconditioned myocardium: effect of loss and reinstatement of cardioprotection. J Mol Cell Cardiol (2001) 33:1571–1588.[CrossRef][Web of Science][Medline]
  19. Loke K.E., McConnell P.I., Tuzman J.M., Shesely E.G., Smith C.J., Stackpole C.J., et al. Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res (1999) 84:840–845.[Abstract/Free Full Text]
  20. Marber M.S., Latchman D.S., Walker J.M., Yellon D.M. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation (1993) 88:1264–1272.[Abstract/Free Full Text]
  21. Marber M.S., Mestril R., Chi S.H., Sayen M.R., Yellon D.M., Dillmann W.H. Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest (1995) 95:1446–1456.[Web of Science][Medline]
  22. Murry C.E., Richard V.J., Reimer K.A., Jennings R.B. Ischemic preconditionins slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res (1990) 66:913–931.[Abstract/Free Full Text]
  23. Nakane M., Klinghofer V., Kuk J.E., Donnelly J.L., Budzik G.P., Pollock J.S., et al. Novel potent and selective inhibitors of inducible nitric oxide synthase. Mol Pharmacol (1995) 47:831–834.[Abstract]
  24. Recchia F.A., McConnell P.I., Loke K.E., Xu X., Ochoa M., Hintze T.H. Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res (1999) 44:325–332.[Abstract/Free Full Text]
  25. Rooke G.A., Feigl E.O. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. Circ Res (1982) 50:273–286.[Abstract/Free Full Text]
  26. Setty S., Tune J.D., Downey H.F. Nitric oxide modulates right ventricular flow and oxygen consumption during norepinephrine infusion. Am J Physiol (2002) 282:H696–H703.[Web of Science]
  27. Shen W., Hintze T.H., Wolin M.S. Nitric oxide. An important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation (1995) 92:3505–3512.[Abstract/Free Full Text]
  28. Shen W., Tian R., Saupe K.W., Spindler M., Ingwall J.S. Endogenous nitric oxide enhances coupling between O2 consumption and ATP synthesis in guinea pig hearts. Am J Physiol (2001) 281:H838–H846.[Web of Science]
  29. Shen W., Xu X., Ochoa M., Zhao G., Bernstein R.D., Forfia P., et al. Endogenous nitric oxide in the control of skeletal muscle oxygen extraction during exercise. Acta Physiol Scand (2000) 168:675–686.[CrossRef][Web of Science][Medline]
  30. Shen W., Xu X., Ochoa M., Zhao G., Wolin M.S., Hintze T.H. Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. Circ Res (1994) 75:1086–1095.[Abstract/Free Full Text]
  31. Shen Y.T., Vatner S.F. Differences in myocardial stunning following coronary artery occlusion in conscious dogs, pigs and baboons. Am J Physiol (1996) 270:H1312–H1322.[Web of Science][Medline]
  32. Sherman A.J., Davis C.A. III, Klocke F.J., Harris K.R., Srinivasan G., Yaacoub A.S., et al. Blockade of nitric oxide synthesis reduces myocardial oxygen consumption in vivo. Circulation (1997) 95:1328–1334.[Abstract/Free Full Text]
  33. Sun J.Z., Tang X.L., Knowlton A.A., Park S.W., Qiu Y., Bolli R. Late preconditioning against myocardial stunning. An endogenous protective mechanism that confers resistance to postischemic dysfunction 24 h after brief ischemia in conscious pigs. J Clin Invest (1995) 95:388–403.[Web of Science][Medline]
  34. Tada H., Thompson C.I., Recchia F.A., Loke K.E., Ochoa M., Smith C.J., et al. Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res (2000) 86:270–274.[Abstract/Free Full Text]
  35. Tanoue Y., Herijgers P., Meuris B., Verbeken E., Leunens V., Lox M., et al. Ischemic preconditioning reduces unloaded myocardial oxygen consumption in an in-vivo sheep model. Cardiovasc Res (2002) 55:633–641.[Abstract/Free Full Text]
  36. Traverse J.H., Chen Y., Hou M., Bache R.J. Inhibition of NO production increases myocardial blood flow and oxygen consumption in congestive heart failure. Am J Physiol (2002) 282:H2278–H2283.[Web of Science]
  37. Trochu J.N., Bouhour J.B., Kaley G., Hintze T.H. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res (2000) 87:1108–1117.[Abstract/Free Full Text]
  38. Tune J.D., Richmond K.N., Gorman M.W., Feigl E.O. Role of nitric oxide and adenosine in control of coronary blood flow in exercising dogs. Circulation (2000) 101:2942–2948.[Abstract/Free Full Text]
  39. Wang Y., Kodani E., Wang J., Zhang S.X., Takano H., Tang X.L., et al. Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2. Circ Res (2004) 95:84–91.[Abstract/Free Full Text]
  40. Xuan Y.T., Tang X.L., Qiu Y., Banerjee S., Takano H., Han H., et al. Biphasic response of cardiac NO synthase isoforms to ischemic preconditioning in conscious rabbits. Am J Physiol (2000) 279:H2360–H2371.[Web of Science]
  41. Yamashita N., Hoshida S., Otsu K., Asahi M., Kuzuya T., Hori M. Involvement of cytokines in the second window of ischaemic preconditioning. Br J Pharmacol (2000) 131:415–422.[CrossRef][Web of Science][Medline]
  42. Yellon D.M., Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev (2003) 83:1113–1151.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Nutr.Home page
G. G. Abdukeyum, A. J. Owen, and P. L. McLennan
Dietary (n-3) Long-Chain Polyunsaturated Fatty Acids Inhibit Ischemia and Reperfusion Arrhythmias and Infarction in Rat Heart Not Enhanced by Ischemic Preconditioning
J. Nutr., October 1, 2008; 138(10): 1902 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Galkin and S. Moncada
S-Nitrosation of Mitochondrial Complex I Depends on Its Structural Conformation
J. Biol. Chem., December 28, 2007; 282(52): 37448 - 37453.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. C. Brown and V. Borutaite
Nitric oxide and mitochondrial respiration in the heart
Cardiovasc Res, July 15, 2007; 75(2): 283 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
L. Lucats, L. Vinet, A. Bize, X. Monnet, D. Morin, J. B. Su, P. Rouet-Benzineb, O. Cazorla, J.-J. Mercadier, L. Hittinger, et al.
The inotropic adaptation during late preconditioning against myocardial stunning is associated with an increase in FKBP12.6
Cardiovasc Res, February 1, 2007; 73(3): 560 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
X. Monnet, L. Lucats, P. Colin, G. Derumeaux, J.-L. Dubois-Rande, L. Hittinger, B. Ghaleh, and A. Berdeaux
Reduction in postsystolic wall thickening during late preconditioning
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H158 - H164.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D. Garcia-Dorado, J. Vinten-Johansen, and H. M. Piper
Bringing preconditioning and postconditioning into focus
Cardiovasc Res, May 1, 2006; 70(2): 167 - 169.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Monnet, X.
Right arrow Articles by Berdeaux, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monnet, X.
Right arrow Articles by Berdeaux, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?